Table 3 Clinical information in each case of NELL-1–associated MN.

From: Prevalence of neural epidermal growth factor-like 1- and exostosin 1/exostosin 2-associated membranous nephropathy: a single-center retrospective study in Japan

Case

Age

Sex

Proteinuria (g/day)

Serum creatinine (mg/dl)

Serum albumin (g/dl)

Complications

Clinical diagnosis

Immunosuppressive therapy

Time to remission

1

68

Male

1.2

0.51

2.0

Rheumatoid arthritis

Secondary MN (autoimmune disease)

Prednisolone

 < 6 months

2

67

Male

Not available

0.83

1.7

Rheumatoid arthritis

Secondary MN (anti-rheumatoid drug)

Prednisolone + Cyclophosphamide

 < 6 months

3

78

Male

5.5

1.99

2.1

DM

Secondary MN (NSAIDs-induced)

None

NA

4

64

Male

4

1.22

1.8

DM, ANA, anti-ssDNA

Primary MN (IgG4+)

None

Not yet; 12 months pass

  1. DM diabetes mellitus, ANA antinuclear antibody, ssDNA Ab single strand DNA antibody, MN membranous nephropathy, NSAIDs nonsteroidal anti-inflammatory drugs, NA not available.
Back to article page